Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 321

1.

Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.

Tengvall K, Huang J, Hellström C, Kammer P, Biström M, Ayoglu B, Lima Bomfim I, Stridh P, Butt J, Brenner N, Michel A, Lundberg K, Padyukov L, Lundberg IE, Svenungsson E, Ernberg I, Olafsson S, Dilthey AT, Hillert J, Alfredsson L, Sundström P, Nilsson P, Waterboer T, Olsson T, Kockum I.

Proc Natl Acad Sci U S A. 2019 Aug 2. pii: 201902623. doi: 10.1073/pnas.1902623116. [Epub ahead of print]

PMID:
31375628
2.

Earnings among people with multiple sclerosis compared to references, in total and by educational level and type of occupation: a population-based cohort study at different points in time.

Wiberg M, Murley C, Tinghög P, Alexanderson K, Palmer E, Hillert J, Stenbeck M, Friberg E.

BMJ Open. 2019 Jul 11;9(7):e024836. doi: 10.1136/bmjopen-2018-024836.

3.

Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden.

Gyllensten H, Kavaliunas A, Murley C, Alexanderson K, Hillert J, Tinghög P, Friberg E.

Mult Scler J Exp Transl Clin. 2019 Jun 28;5(2):2055217319858383. doi: 10.1177/2055217319858383. eCollection 2019 Apr-Jun.

4.

Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis.

McKay KA, Manouchehrinia A, Berrigan L, Fisk JD, Olsson T, Hillert J.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1546. [Epub ahead of print]

PMID:
31206130
5.

Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden.

Karampampa K, Gyllensten H, Yang F, Murley C, Friberg E, Hillert J, Alexanderson K.

Pharmacoecon Open. 2019 Jun 11. doi: 10.1007/s41669-019-0150-3. [Epub ahead of print]

6.

Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment.

Bedri SK, Nilsson OB, Fink K, Månberg A, Hamsten C, Ayoglu B, Manouchehrinia A, Nilsson P, Olsson T, Hillert J, Grönlund H, Glaser A.

PLoS One. 2019 May 29;14(5):e0217208. doi: 10.1371/journal.pone.0217208. eCollection 2019.

7.

Long-term disability progression of pediatric-onset multiple sclerosis.

McKay KA, Hillert J, Manouchehrinia A.

Neurology. 2019 Jun 11;92(24):e2764-e2773. doi: 10.1212/WNL.0000000000007647. Epub 2019 May 15.

8.

Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.

Beiki O, Frumento P, Bottai M, Manouchehrinia A, Hillert J.

JAMA Neurol. 2019 Jun 1;76(6):665-671. doi: 10.1001/jamaneurol.2019.0330.

PMID:
30882868
9.

Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study.

Crielaard L, Kavaliunas A, Ramanujam R, Olsson T, Hillert J, Stridh P, Kockum I, Manouchehrinia A.

J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):761-767. doi: 10.1136/jnnp-2018-319913. Epub 2019 Mar 1.

PMID:
30824631
10.

Cognitive function predicts work disability among multiple sclerosis patients.

Kavaliunas A, Tinghög P, Friberg E, Olsson T, Alexanderson K, Hillert J, Karrenbauer VD.

Mult Scler J Exp Transl Clin. 2019 Jan 14;5(1):2055217318822134. doi: 10.1177/2055217318822134. eCollection 2019 Jan-Mar.

11.

Spatial distribution of multiple sclerosis lesions in the cervical spinal cord.

Eden D, Gros C, Badji A, Dupont SM, De Leener B, Maranzano J, Zhuoquiong R, Liu Y, Granberg T, Ouellette R, Stawiarz L, Hillert J, Talbott J, Bannier E, Kerbrat A, Edan G, Labauge P, Callot V, Pelletier J, Audoin B, Rasoanandrianina H, Brisset JC, Valsasina P, Rocca MA, Filippi M, Bakshi R, Tauhid S, Prados F, Yiannakas M, Kearney H, Ciccarelli O, Smith SA, Andrada Treaba C, Mainero C, Lefeuvre J, Reich DS, Nair G, Shepherd TM, Charlson E, Tachibana Y, Hori M, Kamiya K, Chougar L, Narayanan S, Cohen-Adad J.

Brain. 2019 Mar 1;142(3):633-646. doi: 10.1093/brain/awy352.

PMID:
30715195
12.

Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study.

Song J, Westerlind H, McKay KA, Almqvist C, Stridh P, Kockum I, Hillert J, Manouchehrinia A.

J Neurol. 2019 Feb;266(2):481-486. doi: 10.1007/s00415-018-9163-6. Epub 2018 Dec 21.

13.

Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.

Castelo-Branco A, Landfeldt E, Svedbom A, Löfroth E, Kavaliunas A, Hillert J.

Eur J Neurol. 2019 Apr;26(4):603-609. doi: 10.1111/ene.13863. Epub 2019 Jan 10.

PMID:
30414299
14.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
15.

The association between multiple sclerosis and pain medications.

Burkill S, Montgomery S, Kockum I, Piehl F, Strid P, Hillert J, Alfredsson L, Olsson T, Bahmanyar S.

Pain. 2019 Feb;160(2):424-432. doi: 10.1097/j.pain.0000000000001429. Erratum in: Pain. 2019 Apr;160(4):986.

PMID:
30376533
16.

Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks.

Gros C, De Leener B, Badji A, Maranzano J, Eden D, Dupont SM, Talbott J, Zhuoquiong R, Liu Y, Granberg T, Ouellette R, Tachibana Y, Hori M, Kamiya K, Chougar L, Stawiarz L, Hillert J, Bannier E, Kerbrat A, Edan G, Labauge P, Callot V, Pelletier J, Audoin B, Rasoanandrianina H, Brisset JC, Valsasina P, Rocca MA, Filippi M, Bakshi R, Tauhid S, Prados F, Yiannakas M, Kearney H, Ciccarelli O, Smith S, Treaba CA, Mainero C, Lefeuvre J, Reich DS, Nair G, Auclair V, McLaren DG, Martin AR, Fehlings MG, Vahdat S, Khatibi A, Doyon J, Shepherd T, Charlson E, Narayanan S, Cohen-Adad J.

Neuroimage. 2019 Jan 1;184:901-915. doi: 10.1016/j.neuroimage.2018.09.081. Epub 2018 Oct 6.

PMID:
30300751
17.

The Swedish motor neuron disease quality registry.

Longinetti E, Regodón Wallin A, Samuelsson K, Press R, Zachau A, Ronnevi LO, Kierkegaard M, Andersen PM, Hillert J, Fang F, Ingre C.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):528-537. doi: 10.1080/21678421.2018.1497065. Epub 2018 Oct 9.

PMID:
30296856
18.

Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden.

Gyllensten H, Kavaliunas A, Alexanderson K, Hillert J, Tinghög P, Friberg E.

Mult Scler J Exp Transl Clin. 2018 Jul 9;4(3):2055217318783352. doi: 10.1177/2055217318783352. eCollection 2018 Jul-Sep.

19.

The long-term impact of multiple sclerosis on the risk of divorce.

Landfeldt E, Castelo-Branco A, Svedbom A, Löfroth E, Kavaliunas A, Hillert J.

Mult Scler Relat Disord. 2018 Aug;24:145-150. doi: 10.1016/j.msard.2018.07.002. Epub 2018 Jul 3.

PMID:
30007180
20.

Predicting risk of secondary progression in multiple sclerosis: A nomogram.

Manouchehrinia A, Zhu F, Piani-Meier D, Lange M, Silva DG, Carruthers R, Glaser A, Kingwell E, Tremlett H, Hillert J.

Mult Scler. 2019 Jul;25(8):1102-1112. doi: 10.1177/1352458518783667. Epub 2018 Jun 18.

PMID:
29911467
21.

Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis.

Manouchehrinia A, Hedström AK, Alfredsson L, Olsson T, Hillert J, Ramanujam R.

Front Neurol. 2018 May 11;9:232. doi: 10.3389/fneur.2018.00232. eCollection 2018.

22.

Personal Income Before and After Diagnosis of Multiple Sclerosis.

Landfeldt E, Castelo-Branco A, Svedbom A, Löfroth E, Kavaliunas A, Hillert J.

Value Health. 2018 May;21(5):590-595. doi: 10.1016/j.jval.2017.09.021. Epub 2017 Nov 15.

PMID:
29753357
23.

Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka.

Gamage SMK, Wijeweera I, Adikari SB, Fink K, Hillert J, Fogdell-Hahn A, Sominanda HMA.

Mult Scler Int. 2018 Feb 28;2018:5342936. doi: 10.1155/2018/5342936. eCollection 2018.

24.

Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.

Piehl F, Hillert J.

Mult Scler. 2018 Aug;24(9):1157-1159. doi: 10.1177/1352458518757930. Epub 2018 Feb 22. No abstract available.

PMID:
29468952
25.

The long-term impact of early treatment of multiple sclerosis on the risk of disability pension.

Landfeldt E, Castelo-Branco A, Svedbom A, Löfroth E, Kavaliunas A, Hillert J.

J Neurol. 2018 Mar;265(3):701-707. doi: 10.1007/s00415-018-8764-4. Epub 2018 Feb 1.

26.

The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis.

Birkeldh U, Manouchehrinia A, Hietala MA, Hillert J, Olsson T, Piehl F, Kockum IS, Brundin L, Zahavi O, Wahlberg-Ramsay M, Brautaset R, Nilsson M.

Front Neurol. 2017 Dec 13;8:675. doi: 10.3389/fneur.2017.00675. eCollection 2017.

27.

Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations.

Olafsson S, Stridh P, Bos SD, Ingason A, Euesden J, Sulem P, Thorleifsson G, Gustafsson O, Johannesson A, Geirsson AJ, Thorsson AV, Sigurgeirsson B, Ludviksson BR, Olafsson E, Kristjansdottir H, Jonasson JG, Olafsson JH, Orvar KB, Benediktsson R, Bjarnason R, Kristjansdottir S, Gislason T, Valdimarsson T, Mikaelsdottir E, Sigurdsson S, Jonsson S, Rafnar T, Aarsland D, Djurovic S, Fladby T, Knudsen GP, Celius EG, Myhr KM, Grondal G, Steinsson K, Valdimarsson H, Bjornsson S, Bjornsdottir US, Bjornsson ES, Nilsson B, Andreassen OA, Alfredsson L, Hillert J, Kockum IS, Masson G, Thorsteinsdottir U, Gudbjartsson DF, Stefansson H, Hjaltason H, Harbo HF, Olsson T, Jonsdottir I, Stefansson K.

NPJ Genom Med. 2017 Aug 8;2:24. doi: 10.1038/s41525-017-0027-2. eCollection 2017.

28.

Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.

Kavaliunas A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, Glaser A, Olsson T, Alexanderson K, Hillert J.

Mult Scler. 2019 Jan;25(1):104-112. doi: 10.1177/1352458517740212. Epub 2017 Nov 16.

PMID:
29143553
29.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.

Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

PMID:
29050389
30.

Genetic risk factors for pediatric-onset multiple sclerosis.

Gianfrancesco MA, Stridh P, Shao X, Rhead B, Graves JS, Chitnis T, Waldman A, Lotze T, Schreiner T, Belman A, Greenberg B, Weinstock-Guttman B, Aaen G, Tillema JM, Hart J, Caillier S, Ness J, Harris Y, Rubin J, Candee M, Krupp L, Gorman M, Benson L, Rodriguez M, Mar S, Kahn I, Rose J, Roalstad S, Casper TC, Shen L, Quach H, Quach D, Hillert J, Hedstrom A, Olsson T, Kockum I, Alfredsson L, Schaefer C, Barcellos LF, Waubant E; Network of Pediatric Multiple Sclerosis Centers.

Mult Scler. 2017 Oct 1:1352458517733551. doi: 10.1177/1352458517733551. [Epub ahead of print]

31.

Multiple sclerosis treatment effects on plasma cytokine receptor levels.

Bedri SK, Fink K, Manouchehrinia A, Lundström W, Kockum I, Olsson T, Hillert J, Glaser A.

Clin Immunol. 2018 Feb;187:15-25. doi: 10.1016/j.clim.2017.08.023. Epub 2017 Sep 21.

PMID:
28941836
32.

Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012.

Burkill S, Montgomery S, Hajiebrahimi M, Hillert J, Olsson T, Bahmanyar S.

Neurology. 2017 Aug 8;89(6):555-562. doi: 10.1212/WNL.0000000000004216. Epub 2017 Jul 7.

PMID:
28687718
33.

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.

Spelman T, Frisell T, Piehl F, Hillert J.

Mult Scler. 2018 Jul;24(8):1087-1095. doi: 10.1177/1352458517713668. Epub 2017 Jun 26.

PMID:
28649912
34.

The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement.

Hedström AK, Katsoulis M, Hössjer O, Bomfim IL, Oturai A, Sondergaard HB, Sellebjerg F, Ullum H, Thørner LW, Gustavsen MW, Harbo HF, Obradovic D, Gianfrancesco MA, Barcellos LF, Schaefer CA, Hillert J, Kockum I, Olsson T, Alfredsson L.

Eur J Epidemiol. 2017 Oct;32(10):909-919. doi: 10.1007/s10654-017-0250-2. Epub 2017 Jun 8.

35.

Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age.

Gyllensten H, Wiberg M, Alexanderson K, Norlund A, Friberg E, Hillert J, Ernstsson O, Tinghög P.

Eur J Health Econ. 2018 Apr;19(3):435-446. doi: 10.1007/s10198-017-0894-6. Epub 2017 May 9.

36.

Characterization of annual disease progression of multiple sclerosis patients: A population-based study.

Freilich J, Manouchehrinia A, Trusheim M, Baird LG, Desbiens S, Berndt E, Hillert J.

Mult Scler. 2018 May;24(6):786-794. doi: 10.1177/1352458517706252. Epub 2017 May 8.

PMID:
28481159
37.

Overexpression of the Cytokine BAFF and Autoimmunity Risk.

Steri M, Orrù V, Idda ML, Pitzalis M, Pala M, Zara I, Sidore C, Faà V, Floris M, Deiana M, Asunis I, Porcu E, Mulas A, Piras MG, Lobina M, Lai S, Marongiu M, Serra V, Marongiu M, Sole G, Busonero F, Maschio A, Cusano R, Cuccuru G, Deidda F, Poddie F, Farina G, Dei M, Virdis F, Olla S, Satta MA, Pani M, Delitala A, Cocco E, Frau J, Coghe G, Lorefice L, Fenu G, Ferrigno P, Ban M, Barizzone N, Leone M, Guerini FR, Piga M, Firinu D, Kockum I, Lima Bomfim I, Olsson T, Alfredsson L, Suarez A, Carreira PE, Castillo-Palma MJ, Marcus JH, Congia M, Angius A, Melis M, Gonzalez A, Alarcón Riquelme ME, da Silva BM, Marchini M, Danieli MG, Del Giacco S, Mathieu A, Pani A, Montgomery SB, Rosati G, Hillert J, Sawcer S, D'Alfonso S, Todd JA, Novembre J, Abecasis GR, Whalen MB, Marrosu MG, Meloni A, Sanna S, Gorospe M, Schlessinger D, Fiorillo E, Zoledziewska M, Cucca F.

N Engl J Med. 2017 Apr 27;376(17):1615-1626. doi: 10.1056/NEJMoa1610528.

38.

Comparing costs of illness of multiple sclerosis in three different years: A population-based study.

Gyllensten H, Wiberg M, Alexanderson K, Friberg E, Hillert J, Tinghög P.

Mult Scler. 2018 Apr;24(4):520-528. doi: 10.1177/1352458517702549. Epub 2017 Apr 3.

PMID:
28367678
39.

Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS.

Gianfrancesco MA, Stridh P, Rhead B, Shao X, Xu E, Graves JS, Chitnis T, Waldman A, Lotze T, Schreiner T, Belman A, Greenberg B, Weinstock-Guttman B, Aaen G, Tillema JM, Hart J, Caillier S, Ness J, Harris Y, Rubin J, Candee M, Krupp L, Gorman M, Benson L, Rodriguez M, Mar S, Kahn I, Rose J, Roalstad S, Casper TC, Shen L, Quach H, Quach D, Hillert J, Bäärnhielm M, Hedstrom A, Olsson T, Kockum I, Alfredsson L, Metayer C, Schaefer C, Barcellos LF, Waubant E; Network of Pediatric Multiple Sclerosis Centers.

Neurology. 2017 Apr 25;88(17):1623-1629. doi: 10.1212/WNL.0000000000003849. Epub 2017 Mar 29.

40.

Age Related Multiple Sclerosis Severity Score: Disability ranked by age.

Manouchehrinia A, Westerlind H, Kingwell E, Zhu F, Carruthers R, Ramanujam R, Ban M, Glaser A, Sawcer S, Tremlett H, Hillert J.

Mult Scler. 2017 Dec;23(14):1938-1946. doi: 10.1177/1352458517690618. Epub 2017 Feb 3.

41.

The External Validity of Mapping MSIS-29 on EQ-5D Among Individuals With Multiple Sclerosis in Sweden.

Ernstsson O, Tinghög P, Alexanderson K, Hillert J, Burström K.

MDM Policy Pract. 2017 Feb 1;2(1):2381468317692806. doi: 10.1177/2381468317692806. eCollection 2017 Jan-Jun.

42.

Similar familial risk in multiple sclerosis subgroups.

Song J, Karrenbauer V, Manouchehrinia A, Almqvist C, Hillert J, Westerlind H.

Mult Scler. 2017 Nov;23(13):1782-1785. doi: 10.1177/1352458516684214. Epub 2017 Jan 16.

PMID:
28090800
43.

Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Trojano M, Tintore M, Montalban X, Hillert J, Kalincik T, Iaffaldano P, Spelman T, Sormani MP, Butzkueven H.

Nat Rev Neurol. 2017 Feb;13(2):105-118. doi: 10.1038/nrneurol.2016.188. Epub 2017 Jan 13. Review.

PMID:
28084327
44.

Income in Multiple Sclerosis Patients with Different Disease Phenotypes.

Kavaliunas A, Manouchehrinia A, Danylaite Karrenbauer V, Gyllensten H, Glaser A, Alexanderson K, Hillert J.

PLoS One. 2017 Jan 12;12(1):e0169460. doi: 10.1371/journal.pone.0169460. eCollection 2017.

45.

Causal Effect of Genetic Variants Associated With Body Mass Index on Multiple Sclerosis Susceptibility.

Gianfrancesco MA, Glymour MM, Walter S, Rhead B, Shao X, Shen L, Quach H, Hubbard A, Jónsdóttir I, Stefánsson K, Strid P, Hillert J, Hedström A, Olsson T, Kockum I, Schaefer C, Alfredsson L, Barcellos LF.

Am J Epidemiol. 2017 Feb 1;185(3):162-171. doi: 10.1093/aje/kww120.

46.

Clinical course of multiple sclerosis: A nationwide cohort study.

Manouchehrinia A, Beiki O, Hillert J.

Mult Scler. 2017 Oct;23(11):1488-1495. doi: 10.1177/1352458516681197. Epub 2016 Dec 12.

PMID:
27956559
47.

How does work disability of patients with MS develop before and after diagnosis? A nationwide cohort study with a reference group.

Gyllensten H, Wiberg M, Alexanderson K, Hillert J, Tinghög P.

BMJ Open. 2016 Nov 17;6(11):e012731. doi: 10.1136/bmjopen-2016-012731.

48.

Importance of early treatment initiation in the clinical course of multiple sclerosis.

Kavaliunas A, Manouchehrinia A, Stawiarz L, Ramanujam R, Agholme J, Hedström AK, Beiki O, Glaser A, Hillert J.

Mult Scler. 2017 Aug;23(9):1233-1240. doi: 10.1177/1352458516675039. Epub 2016 Oct 17.

PMID:
27754943
49.

Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk.

Rhead B, Bäärnhielm M, Gianfrancesco M, Mok A, Shao X, Quach H, Shen L, Schaefer C, Link J, Gyllenberg A, Hedström AK, Olsson T, Hillert J, Kockum I, Glymour MM, Alfredsson L, Barcellos LF.

Neurol Genet. 2016 Sep 13;2(5):e97. doi: 10.1212/NXG.0000000000000097. eCollection 2016 Oct.

50.

Re: Declines in the diagnosis of primary progressive MS-A critical change in phenotype or critical measurement error?

Westerlind H, Stawiarz L, Fink K, Hillert J, Manouchehrinia A.

Mult Scler. 2017 Feb;23(2):305-307. doi: 10.1177/1352458516669863. Epub 2016 Sep 28. No abstract available.

PMID:
27650518

Supplemental Content

Loading ...
Support Center